An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

被引：0

作者：

Saiag, P. ^{[1
]}

Robert, C. ^{[2
]}

Grob, J. J. ^{[3
,4
]}

Mortier, L. ^{[5
]}

Dereure, O. ^{[6
]}

Lebbe, C. ^{[7
]}

Mansard, S. ^{[8
]}

Grange, F. ^{[9
]}

Neidhardt, E-M. ^{[10
]}

Lesimple, T. ^{[11
]}

Machet, L. ^{[12
,13
]}

Bedane, C. ^{[14
]}

Jeudy, G. ^{[15
]}

Aubin, F. ^{[16
]}

Dreno, B. ^{[17
]}

Szenik, A. ^{[18
]}

Denden, A. ^{[18
]}

Dutriaux, C. ^{[19
]}

机构：

[1] Ambroise Pare Hosp, AP HP, Dept Dermatol, Boulogne, France

[2] Inst Gustave Roussy, Dept Dermatol, Villejuif, France

[3] Aix Marseille Univ, Dept Dermatol, Marseille, France

[4] Univ Hosp Timone, APHM, Marseille, France

[5] Hop Claude Huriez, Dept Dermatol, Lille, France

[6] CHU Montpellier, Dept Dermatol, Montpellier, France

[7] Hop St Louis, Dept Dermatol Oncol, Paris, France

[8] CHU Estaing, Dept Dermatol, Clermont Ferrand, France

[9] Hosp Robert Debre, CHU Reims, Dept Dermatol, Reims, France

[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[11] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France

[12] CHRU Tours, Dept Dermatol, Tours, France

[13] Univ Francois Rabelais Tours, Tours, France

[14] Hop Dupuytren, CHU Limoges, Dept Dermatol, Limoges, France

[15] Dijon Univ Hosp, Dept Dermatol, Dijon, France

[16] Besancon Univ Hosp, Dept Dermatol, EA3181, Besancon, France

[17] Ctr Hosp Univ Nantes, Dept Dermatol, Nantes, France

[18] Novartis Pharma France, Dept Med Oncol, Rueil Malmaison, France

[19] Hop St Andre, CHU Bordeaux, Dept Dermatol, Bordeaux, France

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1260P

引用

页数：2

共 50 条

[31] A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma
Steinberg, Joyce Leta
Bedikian, Agop Y.
Ernst, D. Scott
Chmielowski, Bartosz
Redman, Bruce
Keating, Anne Therese
Jie, Fei
Chen, Caroline
Weber, Jeffrey S.
Kudchadkar, Ragini Reiney
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
Kudchadkar, Ragini
Ernst, Scott
Chmielowski, Bartosz
Redman, Bruce G.
Steinberg, Joyce
Keating, Anne
Jie, Fei
Chen, Caroline
Gonzalez, Rene
Weber, Jeffrey
CANCER MEDICINE, 2015, 4 (05): : 643 - 650
[33] Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
Yasutomo Teshima
Minako Kizaki
Ryohei Kurihara
Ryosuke Kano
Miki Harumiya
International Journal of Clinical Oncology, 2020, 25 : 1870 - 1878
[34] Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
Teshima, Yasutomo
Kizaki, Minako
Kurihara, Ryohei
Kano, Ryosuke
Harumiya, Miki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1870 - 1878
[35] Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial
Nathan, P.
Grob, J. J.
Dummer, R.
Ascierto, P. A.
Ribas, A.
Robert, C.
Schadendorf, D.
Flaherty, K. T.
Tawbi, H. A.
Hauschild, A.
Mandala, M.
Shah, R.
Banerjee, H.
Sarkar, R. P.
Lau, M. R.
Long, G. V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S921 - S922
[36] Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma
Latimer, Nicholas R.
Amonkar, Mayur M.
Stapelkamp, Ceilidh
Sun, Peng
MELANOMA RESEARCH, 2015, 25 (06) : 528 - 536
[37] Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma
Latimer, Nicholas
Amonkar, Mayur
Stapelkamp, Ceilidh
Sun, Peng
CANCER RESEARCH, 2014, 74 (19)
[38] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Robert, C.
Karaszewska, B.
Schachter, J.
Rutkowski, P.
Mackiewicz, A.
Stroyakovskiy, D.
Lichinitser, M.
Dummer, R.
Grange, F.
Mortier, L.
Chiarion-Sileni, V.
Drucis, K.
Krajsova, I.
Hauschild, A.
Mookerjee, B.
Legos, J.
Schadendorf, D.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664
[39] Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
Mao, Lili
Ding, Ya
Bai, Xue
Sheng, Xinan
Dai, Jie
Chi, Zhihong
Cui, Chuanliang
Kong, Yan
Fan, Yun
Xu, Yanjun
Wang, Xuan
Tang, Bixia
Lian, Bin
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Caili
Guo, Jun
Zhang, Xiaoshi
Si, Lu
FRONTIERS IN ONCOLOGY, 2021, 11
[40] Long-term benefit of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: Five-year analysis of COMBI-AD.
Hauschild, Axel
Dummer, Reinhard
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Kirkwood, John M.
Sileni, Vanna Chiarion
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew Mark
Robert, Caroline
Mortier, Laurent
Schachter, Jacob
Dasgupta, Kohinoor
Gasal, Eduard
Tan, Monique
Long, Georgina V.
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →